Publications

PLoS One

Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS

11-01-2013

Cancer discovery

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

01-01-2013

Cancer research

A preclinical mouse model of invasive lobular breast cancer metastasis.

01-01-2013

Genes Dev.: Genes & development

BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny

27-12-2012

The Journal of pathology

Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland.

01-11-2012

PloS one

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

03-10-2012

Nature reviews. Cancer

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

01-09-2012

Cancer prevention research (Philadelphia, Pa.)

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

01-08-2012

Cancer discovery

Tracking evolution of BRCA1-associated breast cancer.

01-06-2012

Cancer research

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

01-05-2012

Nat Med: Nature medicine

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

06-03-2012

Drug Resist Updates: reviews and commentaries in antimicrobial and anticancer chemotherapy

A rapidly growing number of therapeutics targeting tumor cell-intrinsic and -extrinsic processes is under development for individualized treatment of cancer patients

01-03-2012

Mol Cell Proteomics: Molecular & cellular proteomics: MCP

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer

24-02-2012

Nature

Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.

22-02-2012

Current opinion in genetics & development

Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.

01-02-2012

Cellular and molecular life sciences : CMLS

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

01-01-2012

Cancer cell

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

13-12-2011

Genome research

High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors.

01-12-2011

Hum Mutat: Human mutation

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

03-11-2011

BioEssays : news and reviews in molecular, cellular and developmental biology

Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models.

01-09-2011

Gut

Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer

24-08-2011

Nucleic acids research

Computational identification of insertional mutagenesis targets for cancer gene discovery.

01-08-2011

J Clin Invest: The Journal of clinical investigation

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance

11-07-2011

The Journal of pathology

Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.

01-05-2011

Disease models & mechanisms

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

01-05-2011

The Journal of pathology

Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system.

01-05-2011

Journal of mammary gland biology and neoplasia

Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

01-04-2011

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model.

01-12-2010

BMC cancer

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.

30-11-2010

Nat Struct Mol Biol.: Nature structural & molecular biology

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping

14-11-2010

BMC research notes

KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data.

11-11-2010

Genome Biology

Somatic structural rearrangements in genetically engineered mouse mammary tumors

13-10-2010

Cell cycle (Georgetown, Tex.)

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

15-09-2010

Nanotechnology

A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node.

03-09-2010

BMC cancer

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.

24-08-2010

Trends Pharmacol Sci.: Trends in pharmacological sciences

Targeting homologous recombination repair defects in cancer

01-08-2010

Nature structural & molecular biology

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

01-06-2010

Nature cell biology

BRD7 is a candidate tumour suppressor gene required for p53 function.

01-04-2010

Cancer research

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

15-02-2010

Cancer Research

Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach

26-01-2010

Cancer research

Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.

15-01-2010

Oncogene

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

07-01-2010

PLoS computational biology

Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach.

01-01-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

01-01-2010

The Journal of pathology

A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis.

01-01-2010

Proc Natl Acad Sci U S A: Proceedings of the National Academy of Sciences of the United States of America

Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia

22-12-2009

Methods in molecular biology (Clifton, N.J.)

Studying drug resistance using genetically engineered mouse models for breast cancer.

02-12-2009

Biochimica et biophysica acta

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

01-12-2009

British journal of cancer

Preclinical mouse models for BRCA1-associated breast cancer.

17-11-2009

Breast cancer research : BCR

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

28-08-2009